Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
dc.contributor.author | Fizazi, K. | en |
dc.contributor.author | Greco, F. A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.creator | Fizazi, K. | en |
dc.creator | Greco, F. A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.date.accessioned | 2018-06-22T09:53:02Z | |
dc.date.available | 2018-06-22T09:53:02Z | |
dc.date.issued | 2011 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41626 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Cisplatin | en |
dc.subject | Etoposide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Mammography | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Drug safety | en |
dc.subject | Gemcitabine | en |
dc.subject | Oxaliplatin | en |
dc.subject | Cancer staging | en |
dc.subject | Docetaxel | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Outcome assessment | en |
dc.subject | Clinical practice | en |
dc.subject | Irinotecan | en |
dc.subject | Platinum complex | en |
dc.subject | Risk assessment | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Follow-up studies | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Sunitinib | en |
dc.subject | Practice guideline | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Cancer localization | en |
dc.subject | Alpha fetoprotein | en |
dc.subject | Prostate specific antigen | en |
dc.subject | Protein blood level | en |
dc.subject | Unspecified side effect | en |
dc.subject | Somatostatin derivative | en |
dc.subject | Capecitabine | en |
dc.subject | Chorionic gonadotropin | en |
dc.subject | Everolimus | en |
dc.subject | Streptozocin | en |
dc.title | Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdr389 | |
dc.description.volume | 22 | |
dc.description.issue | SUPPL. 6 | en |
dc.description.startingpage | vi64 | |
dc.description.endingpage | vi68 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |